A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
A phase 1/2 trial of Trastuzumab deruxtecan, Durvalumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04538742 by AstraZeneca, with 245 participants enrolled, started 2020-12-28 and due to reach its primary completion in 2025-01-31. Interventions recorded: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab and Tucatinib.
Similar pages
not linked directly; found by shared links- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca, HER2-positive breast cancer and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Tucatinib, Pertuzumab, Daiichi Sankyo, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Daiichi Sankyo, Durvalumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
- TrialAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Shares Daiichi Sankyo, Durvalumab, AstraZeneca and the tag pipeline.